share_log

康方生物:自願公告 - 卡度尼利聯合化療一線治療胃或胃食管結合部腺癌的III期臨床試驗(AK104 -302)的期中分析達到總生存期(OS)主要終點

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT

香港交易所 ·  Nov 6, 2023 18:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more